Overview of Yong Qi

What is Yong Qi? (Azithromycin)

Property	Description
Active ingredient	Azithromycin
Form	Tablet, Capsule, Oral Suspension, IV Solution
Pharmacological class	Antibiotic (Azalide subclass of Macrolides)
Common use	Resolving bacterial infections
Origin	Semi-synthetic

The medicine Yong Qi is a prescription-only antibiotic used specifically to control infections caused by susceptible bacteria. It contains the active ingredient Azithromycin and is classified as a macrolide antimicrobial. Azithromycin is the prototype of the azalide subclass, which is characterized by a structural modification that alters its pharmacological behavior, confirming that the medicine is designed to combat bacterial threats and is ineffective against viral infections.

Composition, Origin, and Unique Differentiation

The core component of Yong Qi is the active ingredient Azithromycin, a single-entity product derived through semi-synthetic processes. Its distinctive structure provides it with excellent tissue penetration and a long half-life compared to older macrolide drugs. This unique pharmacokinetic profile allows the drug to concentrate effectively in infected tissues, a key differentiating factor that often permits shorter treatment regimens. Yong Qi is generally available for oral administration in multiple dosage forms, including tablets and oral suspension, as well as a powder for intravenous injection in clinical settings.

General Purpose of This Azalide Compound

The general purpose of Yong Qi is to resolve confirmed bacterial infections by preventing the spread of harmful microorganisms. Azithromycin achieves this by interfering with the bacteria's growth process, primarily acting as a bacteriostatic agent. It works at the molecular level by inhibiting the synthesis of proteins required for the bacteria to multiply and survive. As a broad-spectrum agent, it is effective against a variety of pathogens, and its use is typically confined to bacterial scenarios, such as certain respiratory or skin infections.

Regulatory References

What side effects are possible with Yong Qi?

The searches conducted for an official regulatory label or product insert for the drug Yong Qi did not yield specific documentation from governmental authorities (such as the FDA, EMA, or NMPA) detailing its adverse reactions or safety profile. The following safety information is derived from general regulatory guidelines that govern pharmaceutical products, particularly those related to Traditional Chinese Medicine (TCM), in the absence of a specific label.

Yong Qi: Possible side effects and safety information

The safety profile of any regulated medicine is structured around continuous monitoring, and the reported risks are generally classified based on their nature, severity, and frequency.

Adverse Reaction Classification

Specific categories of side effects (e.g., gastrointestinal, dermatologic) and their frequency (very common, rare, etc.) cannot be listed without an authoritative product label. However, the regulatory system mandates continuous assessment of all reported Adverse Drug Reactions (ADRs).

Serious Adverse Reactions (SARs): Governmental pharmacovigilance systems define SARs as any adverse event that results in death, is life-threatening, requires or prolongs patient hospitalization, causes persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. All SARs must be reported promptly.
Regulatory Monitoring: Manufacturers are responsible for the ongoing collection and evaluation of safety data to ensure that the official product label and package insert reflect the current understanding of the drug's risks. New safety concerns identified post-marketing require prompt revision of the documentation.

Population-Specific and Use-Related Safety Considerations

Regulatory standards require consideration of populations that may be at higher risk for adverse events, such as the elderly, patients with pre-existing conditions (e.g., liver or kidney impairment), and those taking multiple medications. In the context of Traditional Chinese Medicine formulations, improper use, including erroneous substitution of ingredients, quality defects, over-consumption, or incorrect preparation, can lead to adverse reactions.

The overall understanding of risk for this product is structured by the national pharmacovigilance requirements that emphasize stringent oversight of all potential negative outcomes. This approach ensures that, as safety data is generated from real-world use, the official guidance regarding risks, restrictions, and necessary monitoring is updated to maintain patient safety.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Yong Qi (Azithromycin) overdose outlines expected clinical manifestations and mandated emergency responses. Overdosage typically presents with symptoms similar to those observed at therapeutic doses, including nausea, vomiting, and diarrhea.

Documented Overdose Profile

Overdose Component	Regulatory Summary
Clinical Manifestations	Symptoms primarily affect the gastrointestinal system. Reversible loss of hearing has also been documented as a manifestation associated with macrolide antibiotic overdose.
Severe Potential Outcome	The risk of prolonged cardiac repolarization and subsequent Torsades de Pointes—a potentially fatal irregular heart rhythm—is an important consideration highlighted in the prescribing information.
Supportive Management	No specific antidote is known for Azithromycin overdose. Management is therefore limited to general symptomatic and supportive measures as clinically indicated.

Mandated Emergency Action

Immediate medical help is required for any suspected overdose. Specifically, contact a poison control helpline right away. Urgent intervention from emergency services must be sought if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Furthermore, the regulatory documentation notes that patients with severe renal impairment may experience altered systemic exposure, a pharmacokinetic factor relevant to high-exposure situations.

Therapeutic Uses of Yong Qi

Yong Qi (Azithromycin) is commonly used for managing infections caused by susceptible bacteria across several key symptomatic domains. Its application may be part of symptomatic management that supports the patient's recovery. It is relevant across multiple therapeutic areas, assisting with easing the overall symptom burden.

The medication is commonly used across conditions presenting with acute episodes associated with conditions like community-acquired pneumonia, acute bacterial infections of the sinuses, episodes of acute worsening of chronic bronchitis, and infections of the skin and middle ear. Its use is also relevant for managing certain urogenital infections caused by specific bacteria.

The primary therapeutic purpose is to provide support that helps ease the overall symptom burden. The medication is used in situations involving certain distressing symptoms. The medication is used to control the spread of bacteria, thereby allowing the body to recover. This supports the patient during difficult episodes by easing distress and may help the patient cope more steadily with temporary physiological imbalance and localized pain and may assist with supporting the patient's general well-being during symptomatic phases.

Quick Fact: Support for Symptoms of Localized Inflammation and Pain

Yong Qi is applied to manage symptom clusters that may become intense, such as local pain, swelling, and redness associated with skin infections or acute otitis media. This contributes to improved day-to-day comfort by easing the inflammatory component and may assist with managing manifestations that interfere with daily functioning.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Yong Qi (Azithromycin) eligibility is defined by regulatory guidelines based on population risks and prior health status, strictly according to official labeling.

Populations Who Must Not Use Yong Qi (Contraindicated)

The medicine is contraindicated for patients with a known hypersensitivity or allergy to azithromycin, erythromycin, or any macrolide/ketolide antibiotic. Use is also strictly prohibited for individuals with a history of cholestatic jaundice or hepatic dysfunction linked to previous azithromycin treatment, or severe liver disease.

Eligibility by Age and Condition

Official regulatory data states that safety and effectiveness have not been established for most indications in patients under 6 months of age. Caution is advised for neonates (under 42 days) due to reports of Infantile Hypertrophic Pyloric Stenosis (IHPS).

Use Requiring Special Caution

Conditional use is required for several high-risk groups. Caution is advised for patients with pre-existing cardiac conditions, specifically known QT interval prolongation or other proarrhythmic states. Restrictions also apply to patients with severe renal impairment (GFR less than 10 mL/min) and those with myasthenia gravis, as the medicine may exacerbate muscle weakness. Oral administration is not recommended for severe systemic infections such as known bacteremia or pneumonia requiring hospitalization.

What should I know about interactions with other medicines?

The interaction profile of Yong Qi (Azithromycin) is based on documented pharmacodynamic and pharmacokinetic patterns, requiring specific caution with several medicinal products and administration timing rules.

Documented Interactions

Classification	Interacting Agents (Examples)	Official Outcome / Restriction
Contraindicated Combination	Ergot derivatives (e.g., Ergotamine)	Use is prohibited due to the theoretical potential for ergotism, based on macrolide class effects.
Pharmacodynamic Risk	QT-prolonging substances (e.g., Amiodarone, Pimozide)	Co-administration requires caution due to the additive risk of QT interval prolongation and cardiac arrhythmia.
Transporter-Mediated Effect	P-glycoprotein (P-gp) substrates (e.g., Digoxin, Ciclosporin)	Azithromycin inhibits P-gp, increasing the serum concentration and exposure of these co-administered medicines, necessitating monitoring.

Other Clinically Relevant Interactions

Co-administration with Nelfinavir is documented to increase the systemic exposure (AUC and Cmax) of azithromycin, warranting close monitoring. Post-marketing reports indicate potentiated anticoagulation with coumarin-type anticoagulants (e.g., Warfarin), which mandates increased monitoring of coagulation times. Concomitant use with Antacids containing aluminum or magnesium requires a timing-based separation rule; the oral dose of azithromycin must be separated by at least one hour before or two hours after the antacid dose to mitigate a reduction in azithromycin's peak plasma concentration. The product label states that azithromycin does not significantly interact with the hepatic Cytochrome P450 system.

Mechanism of Action

The action of Azithromycin, the active component of Yong Qi, occurs across two distinct mechanistic domains. The primary action involves extbfreversible inhibition of bacterial activity. The molecule binds specifically to the extbf23S rRNA within the bacterial extbf50S ribosomal subunit , physically blocking the Nascent Peptide Exit Tunnel. This extbfsteric occlusion prevents the extbfpeptidyl translocation step, immediately halting the elongation and synthesis of proteins essential for cellular function. The result is a extbfbacteriostatic effect that arrests the replication of susceptible organisms.

Separately, the drug exhibits a extbfmodulatory effect on the host's innate immune system. Azithromycin concentrates in extbfphagocytic cells and extbfsuppresses the activation of the extbfNF-kappa extbfB signaling pathway . This intracellular action reduces the production and release of pro-inflammatory extbfcytokines (e.g., IL-8) and alters the extbfchemotaxis of extbfneutrophils. This extbfimmunomodulatory effect assists in the functional extbfregulation of heightened physiological responses driven by cytokines. The mechanism is subject to evasion via extbfTarget Site Modification or extbfActive Drug Efflux pumps.

Dosage and Administration Information

How to Use Yong Qi (Azithromycin)

The administration of Yong Qi is governed by specific instructions detailing the route, dosage, frequency, and relationship to food. The medicine is used in short, defined courses, leveraging its unique pharmacological properties.

Administration Routes and Forms

Route	Forms and Usage
Oral	Primary route for tablets (e.g., 250 mg, 500 mg) and oral suspension. May be a follow-up to IV therapy.
Intravenous (IV)	Reserved for initial therapy in specific severe infections. Must be prepared and administered as a slow infusion over 1 to 3 hours, strictly prohibited as a bolus or intramuscular injection.

Dosing Patterns and Timing

Administration typically follows a single daily dose pattern for all official regimens. Many courses utilize a higher loading dose (e.g., 500 mg) on the first day, followed by lower maintenance doses (e.g., 250 mg) on subsequent days to complete a course of three or five days. The total course duration is predetermined and not adjusted based on symptom relief.

Standard tablets and suspensions can generally be taken with or without food. However, the extended-release oral suspension must be taken on an empty stomach (at least 1 hour before or 2 hours after a meal) to ensure proper absorption.

Special Population and Missed Dosing

For pediatric patients, the correct dose of the oral suspension is determined by the child's body weight (mg/kg). No dose adjustment is typically required for older adults or patients with mild to moderate impairment of the liver or kidneys. If a single daily dose is missed, standard protocols indicate that it should be taken as soon as possible, and the regular schedule should resume the next day; the dose must not be doubled.

Recent Clinical Evidence

Research evidence / Overview of studies for Yong Qi

Evidence for use in Community-Acquired Pneumonia (CAP)

Research has explored Yong Qi in studies concerning Community-Acquired Pneumonia (CAP), a condition involving periods of heightened symptom activity. The evidence base includes many Randomized Controlled Trials (RCTs) and observational studies. Studies have also tracked long-term outcomes, such as patterns of patient survival and patient readmission to the hospital.

Studies described patterns of patient survival that were associated with cohorts receiving a regimen including Yong Qi compared to certain alternative groups. Studies reported measurements of hospital stay duration that were described as shorter in some groups receiving a regimen including the medicine compared to a comparator group. These findings describe group patterns, not personal outcomes, and reflect the specific conditions under which they were conducted. What remains uncertain is the medicine's role as a single agent (monotherapy) in all types of severe or complicated CAP cases.

Evidence for use in Acute Otitis Media

The research concerning middle ear infections in children consists mainly of Systematic Reviews and Comparative RCTs, which have often examined Yong Qi against older, standard antibiotics. These studies were designed to track outcomes related to physical discomfort, such as the resolution of pain, and to monitor the achievement of the clinical endpoint.

Trials tracked patterns of measured symptom resolution that were described as generally similar to those reported for multi-day courses of standard antibiotic therapies. Trial outcomes for children aged two years and younger sometimes described less frequent reported achievement of the clinical endpoint compared to older children in the same study cohorts. Evidence is limited for the safety and effectiveness in infants younger than six months of age, as this age group is not established in the existing clinical research record.

Evidence for use in Acute Exacerbations of Chronic Bronchitis (AECB)

Research has studied Yong Qi for Acute Bacterial Exacerbations of Chronic Bronchitis (AECB). Studies include both short-term RCTs and longer-term, often placebo-controlled trials, evaluating maintenance use. Long-term maintenance trials reported patterns where a lower number of exacerbations was observed in groups associated with the use of the medicine compared to a non-active comparator.

Trials for acute events also described patterns where a lower frequency of patients meeting the criteria for study endpoint failure was observed over a three-month follow-up period. The observed requirement for extended use to sustain the described clinical patterns raises questions about the long-term balance of potential outcomes against risks, including the selection of resistant bacteria.

Key Studies & References

Azithromycin Prophylaxis in Adults with Respiratory Disease (Guidance on Long-Term Use Risks)

Frequently Asked Questions (FAQ)

Common questions about Yong Qi (FAQ)

Q: What is the difference between Yong Qi and other medicines for the same problem?

Official information describes the active ingredient, Azithromycin, as belonging to the azalide subclass of macrolide antibiotics. This classification is linked to the drug having a long elimination half-life, which supports its once-daily dosing and ability to achieve high concentrations in body tissues.

Q: How quickly should someone start to feel a change after starting Yong Qi?

Official drug information indicates that a patient may notice an improvement in their condition during the first few days of treatment. This is a general observation, and individual response patterns can vary.

Q: How long does the effect of one dose of Yong Qi last?

Official pharmacological data indicates that the active ingredient has a long terminal elimination half-life of 68 hours. This characteristic supports the drug's once-daily dosing regimen and short overall treatment courses.

Q: Are the side effects of Yong Qi usually temporary?

Regulatory documents typically do not list a specific duration for most common side effects. However, official warnings note that due to the long tissue half-life, a recurrence of allergic symptoms is a possibility, even after the course of treatment has been stopped.

Q: Why is Yong Qi sometimes given with other medications?

The medicine is sometimes administered in combination with other drugs for specific, approved preventative indications. For instance, it has been used with other medicines to help prevent disseminated Mycobacterium avium complex (MAC) disease in specific patient populations.

Q: Does Yong Qi only treat the symptoms or something else?

Yong Qi's primary mechanism involves stopping bacterial protein synthesis, which is intended to halt the progression of the bacterial infection. Official documents also note that the drug concentrates in inflammatory cells, which may contribute to its influence on inflammation.

Q: Is Yong Qi safe for older adults or seniors?

Clinical studies have generally not indicated differences in the side effect profile in older adults compared to younger adults. However, older patients may be more susceptible to drug-associated effects on the heart's electrical activity, specifically the QT interval. This susceptibility is a known consideration for use in this population.

Q: Are there differences in how Yong Qi is used for adults versus children?

Regulatory documents indicate that the way the dose is determined differs by age. For children, the correct dosage is calculated based on their body weight (milligrams per kilogram). The majority of adult regimens rely on fixed dosing, while the age eligibility for certain indications can also vary.

Q: Is Yong Qi suitable for people under the age of 18?

The drug is approved for various indications in children 6 months of age and older, with specific weight-based dosing for those 2 years and older. Safety and effectiveness have not been established for most uses in infants under 6 months.

Q: Is the dose of Yong Qi based on weight or age?

The dose for pediatric patients is calculated based on their body weight (mg/kg). For older adults, dose adjustments are not typically required based on age alone, provided there are no other major health impairments.

Q: What are the most commonly reported side effects of Yong Qi?

Official regulatory documents list the most common adverse reactions reported in clinical trials as gastrointestinal issues. These typically include nausea (4–5%), diarrhea or loose stools (4–5%), and abdominal pain (3%).

Q: Is it okay to have alcohol while using Yong Qi?

Official sources generally do not cite dangerous drug-alcohol interactions. However, consuming alcohol may worsen common side effects like nausea or dizziness.

Q: Can Yong Qi interact with common over-the-counter pain relievers?

No direct interactions were found with common over-the-counter (OTC) pain relievers like ibuprofen. The absence of a direct interaction is noted, but monitoring is still important for individuals with underlying heart, kidney, or liver conditions.

Q: What are the warnings about using Yong Qi during pregnancy?

Azithromycin is classified as a Pregnancy Category B drug. Animal studies found no evidence of fetal harm, but there are no adequate and well-controlled studies in pregnant women. Official labeling states the medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Q: Why do official documents mention certain lab tests are needed before starting Yong Qi?

Protocols may require specific tests, such as an ECG (a heart recording) and blood tests to check kidney and liver function, before starting this medicine. These checks are related to known considerations for use, particularly the potential for effects on heart rhythm (QT prolongation) and liver function.

Q: Does Yong Qi have a risk of dependence or withdrawal?

The medicine is an antibiotic used for short-term bacterial infections and is not classified as a controlled substance. Regulatory documents do not list dependence or withdrawal symptoms associated with its use.

Q: Can Yong Qi cause changes in mood or behavior?

Yes, post-marketing reports collected by regulatory bodies have included psychiatric adverse reactions. These reported changes in mood or behavior include aggressive reaction and anxiety.

Q: Can Yong Qi affect birth control pills?

The medicine does not typically stop hormonal contraceptives from working. Official information indicates that if the use of the drug results in severe vomiting or diarrhea lasting longer than 24 hours, the effectiveness of oral contraceptive pills may be reduced.

Q: What does the patient information leaflet say about stopping Yong Qi?

Official guidance emphasizes the importance of completing the full course of the medicine as prescribed, even if symptoms show early improvement. For patients on long-term treatment, the medicine should be discontinued only under the direction of a healthcare professional.

Q: Is there a generic version of Yong Qi available?

Yes, the active ingredient in Yong Qi is Azithromycin, which is widely available as a generic drug. It can be found in various forms, including tablets, capsules, and oral suspension.

Q: Are any long-term side effects known for Yong Qi?

While the drug is typically used for short courses, the FDA has issued warnings concerning its use in a specific, high-risk patient population (stem cell transplant recipients). This use was described as being associated with an increased risk of cancer relapse and mortality in that specific patient group.

Q: What is the risk of overdose with Yong Qi?

Official drug information states that in the event of a suspected overdose, emergency medical services should be contacted, such as a Poison Control center.

Q: How is Yong Qi processed by the body (metabolism)?

The drug is eliminated primarily via biliary excretion (through the liver) as unchanged drug. Regulatory information also notes that it does not significantly interact with the hepatic Cytochrome P450 enzyme system.

Q: Can Yong Qi cause sleepiness or drowsiness?

Yes, official reports of adverse reactions have included effects on the nervous system. These documented side effects include somnolence (sleepiness), dizziness, and vertigo.

How should Yong Qi be stored and disposed of?

Storage and Protection Requirements

Official labeling for Yong Qi (Azithromycin) requires specific storage and handling to maintain product integrity.

Dosage Form	Mandatory Storage Condition	In-Use Stability Limit
Tablets	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F); keep container tightly closed.	N/A
Oral Suspension (Reconstituted)	Store at 5 C to 30 C; Do not freeze.	Must be discarded after 10 days.

The medication must always be kept out of the sight and out of the reach of children. The container should be kept tightly closed to protect the product from moisture.

Official Disposal Instructions

Regulatory instructions state that unused or expired Yong Qi must be disposed of according to local regulatory requirements. The medication should not be disposed of by throwing it into household wastewater or general trash unless local guidelines or the drug label specifically allow it.

Yong Qi